Literature DB >> 20153277

Management of an unfortunate triad after breast reconstruction: pyoderma gangrenosum, full-thickness chest wall defect and Acinetobacter Baumannii Infection.

Michael V Schintler1, Martin Grohmann, Claudio Donia, Elisabeth Aberer, Erwin Scharnagl.   

Abstract

If diagnosed late, post-surgical pyoderma gangrenosum (PSPG) is a rare, tricky and potentially life-threatening complication. Once diagnosed, immunosuppressive agents may provoke further complications. Well-intentioned extensive serial debridement may cause deep skin and soft-tissue defects, requiring skin grafting and possible flap surgery. The combination of necessary immunosuppressive treatment, protracted hospital stay and broad-spectrum systemic antimicrobial therapy may encourage serious acquired multidrug resistance (MDR). We report an unfortunate triad following breast reconstruction of PSPG, full-thickness chest wall defect and MDR with Acinetobacter baumannii infection. Interdisciplinary treatment using free flap surgery and negative-pressure wound therapy with instillation therapy (V.A.C.Instill(R) Wound Therapy) enabled survival and complete wound closure. Copyright 2009 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20153277     DOI: 10.1016/j.bjps.2009.12.013

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  10 in total

1.  [Surgical management of Pyoderma gangrenosum].

Authors:  I Sick; B Trautner; T Ruzicka
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

Review 2.  Integrated negative pressure wound therapy system with volumetric automated fluid instillation in wounds at risk for compromised healing.

Authors:  Allen Gabriel
Journal:  Int Wound J       Date:  2012-08       Impact factor: 3.315

Review 3.  Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases.

Authors:  Klaus Eisendle; Tobias Thuile; Jenny Deluca; Maria Pichler
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-04-28       Impact factor: 4.730

Review 4.  Recommendations on negative pressure wound therapy with instillation and antimicrobial solutions - when, where and how to use: what does the evidence show?

Authors:  David A Back; Catharina Scheuermann-Poley; Christian Willy
Journal:  Int Wound J       Date:  2013-12       Impact factor: 3.315

5.  Pyoderma gangrenosum of the breast treated with intravenous immunoglobulin.

Authors:  Sudipta Sinnya; Saud Hamza
Journal:  J Dermatol Case Rep       Date:  2013-06-30

6.  Pyoderma gangrenosum: a review of clinical features and outcomes of 23 cases requiring inpatient management.

Authors:  Mingwei Joel Ye; Joshua Mingsheng Ye
Journal:  Dermatol Res Pract       Date:  2014-10-08

7.  Combination of negative pressure wound therapy and systemic steroid therapy in postsurgical pyoderma gangrenosum after reduction mammoplasty; a case of proven efficacy and safety.

Authors:  Sara Tanini; Gianmarco Calugi; Giulia Lo Russo
Journal:  Dermatol Reports       Date:  2017-12-04

8.  Pyoderma Gangrenosum after Deep Inferior Epigastric Perforator Breast Reconstruction: Systematic Review and Case Report.

Authors:  Justin T Zelones; John F Nigriny
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-04-21

9.  Pyoderma Gangrenosum Masquerading as Necrotizing Infection after Autologous Breast Reconstruction.

Authors:  Tae Hwan Park; Kenneth L Fan; Elizabeth G Zolper; David H Song; Gabriel Del Corral
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-04-10

Review 10.  Dermatologic Complications Following Cosmetic and Reconstructive Plastic Surgery: A Systematic Review of the Literature.

Authors:  Peter J Nicksic; Rebecca L Farmer; Samuel O Poore; Venkat K Rao; Ahmed M Afifi
Journal:  Aesthetic Plast Surg       Date:  2021-07-06       Impact factor: 2.326

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.